Since its establishment in May 2000, microbio has been adhering to the concept of active innovation, focusing on the research and development of high-end products for new medicines and medical care, and gradually forming a biotechnology enterprise group with “innovation” as its core. In-depth development in new drug research and development, organic agriculture and biotechnology venture capital. While achieving corporate development and enhancing shareholders’ rights, we also fulfill our corporate social responsibility and care for our lives.
In terms of new drug research and development, Chemo young and Herbiron have obtained the new drug certificates approved by the Ministry of Health and Welfare, and have successfully developed a variety of microbial pharmaceutical technology platforms, and have repeatedly made major breakthroughs in the field of biotechnology. The Microbio has received many awards and professional awards such as Biomedical Quality Award and Biomedical Innovation Award. At the same time, Microbio continues to uphold professional and rigorous R&D management, combined with the first-class R&D team, to develop high-quality medical and health care products, including Tien Chun Boo, top quality enzyme drinks and Lee Herb series products and other patented leading products.
|2022||The data of SNS812, an anti-Pan-COVID19 siRNA, co-developed by subsidiary Microbio (Shanghai) & Oneness.|
|2022||Microbio Ranked among Top 5% in the 8th Corporate Governance Evaluation|
|2022||Subsidiary received the unblinding data from CRO, engaged by Oneness, regarding US Phase II clinical trial of FB825 to treat moderate-to-severe atopic dermatitis.|
|2022||Microbio Co.,LTD. receives a R.O.C. patent on the new drug MS-20 (CHEMO YOUNG).|
|2022||Microbio (Shanghai) and OneNess jointly developed a new broad-spectrum small nucleic acid drug for the treatment of new coronavirus infection, SNS812, which was approved by the US FDA for Phase I clinical trials|
|2022||Microbio (Shanghai), OneNess and CHO Pharma signed an agreement to jointly develop nucleic acid drug “targeted sugar delivery technology”.|
|2023||Microbio Ranked among Top 5% in the 9th Corporate Governance Evaluation|
|2023||Microbio (Shanghai) and OneNess jointly developed a new broad-spectrum small nucleic acid drug for the treatment of new coronavirus infection, SNS812, which was approved by the TFDA for phase II clinical trials|